<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572049</url>
  </required_header>
  <id_info>
    <org_study_id>MSG15</org_study_id>
    <secondary_id>MSG-15</secondary_id>
    <secondary_id>UTN U1111-1228-5154</secondary_id>
    <nct_id>NCT03572049</nct_id>
  </id_info>
  <brief_title>Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole</brief_title>
  <acronym>MSG15</acronym>
  <official_title>SUBA-itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses: a Multi-center, Open-label Comparative Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, randomized, open-label parallel arm study involving
      patients with proven or probable invasive endemic fungal infection to ascertain the
      pharmacokinetics, safety, efficacy, tolerability and health economics of oral
      SUBA-itraconazole compared to conventional itraconazole. Patients will receive randomized
      open-label study drug (SUBA-itraconazole or conventional itraconazole) over a 42 day period
      and then continue therapy until Day 180. Patients will be stratified based on clinically
      reported infection with the human immunodeficiency virus (HIV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, randomized, open-label parallel arm study involving
      patients with proven or probable invasive endemic fungal infection to ascertain the
      pharmacokinetics, safety, efficacy, and tolerability of oral SUBA-itraconazole or
      itraconazole. Patients will receive randomized open-label study drug (either SUBA-
      itraconazole 130 mg twice daily or itraconazole 200 mg twice daily) over a 42-day period and
      then continue on their assigned open-label therapy until day 180.

      The study sample size will be 80 evaluable patients - target enrollment (three arms:
      approximately 40 histoplasmosis, 20 coccidioidomycosis, 20 other endemic fungal infections).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Plasma Itraconazole Levels and Hydroxyitraconazole levels at Day 14</measure>
    <time_frame>Baseline to Day 14</time_frame>
    <description>Time to achieve therapeutic itraconazole and hydroxyitraconazole levels by evaluating Inter-patient variability as calculated by co-efficient of variation on plasma specimens collected on Day 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to study medication regimens Days 1-42</measure>
    <time_frame>Baseline to Day 42</time_frame>
    <description>The percentage of prescribed capsules returned in capsule count on Day 42</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of treatment related adverse events Days 1-42</measure>
    <time_frame>Baseline to Day 42</time_frame>
    <description>Comparison of the number of treatment related adverse events in each arm occurring Days 1-42.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Plasma Itraconazole Levels and Hydroxyitraconazole levels at Day 42</measure>
    <time_frame>Baseline to day 42</time_frame>
    <description>Percentage of patients with therapeutic itraconazole and hydroxyitraconazole levels as measured in plasma trough levels Day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of signs and symptoms of invasive fungal infection on Day 42</measure>
    <time_frame>Baseline to day 42</time_frame>
    <description>We will measure specific signs and symptoms related to endemic fungal infection, comparing baseline findings to Day 42 findings using physical examination and patient history.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days of Hospitalization at Day 180</measure>
    <time_frame>Baseline to day 180</time_frame>
    <description>The number of days of Hospitalization occurring between Day 1-180</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Fungal Infection</condition>
  <arm_group>
    <arm_group_label>SUBA itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1: Day 1-3 two 65 mg capsules three times daily with food. Days 4-42 two 65 mg capsules twice daily with food.
Stage 2 : Days 43-180 two 65 mg capsules twice daily with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional itraconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stage 1: Day 1-3 two 100 mg capsules three times daily with food. Days 4-42 two 100 mg capsules twice daily with food.
Stage 2 : Days 43-180 two 100 mg capsules twice daily with food</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUBA itraconazole</intervention_name>
    <description>SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.</description>
    <arm_group_label>SUBA itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional itraconazole</intervention_name>
    <description>Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.</description>
    <arm_group_label>Conventional itraconazole</arm_group_label>
    <other_name>itraconazole</other_name>
    <other_name>Sporanox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients age &gt; 18 years who have given written informed consent to
             participate

          2. Patients with a proven or probable endemic mycosis (Histoplasma, Coccidioides,
             Paracoccidioides, Blastomyces, Sporothrix, Talaromyces marneffei (formerly Penicillium
             marneffei) according to current EORTC/MSG (Mycoses Study Group) criteria, including
             patients who:

               -  Are immunosuppressed, including as a result of HIV/AIDS

               -  Have had a heart, lung or bone marrow transplant

               -  Have had chemotherapy for cancer

               -  Are otherwise normal hosts

        Exclusion Criteria:

          1. Significant liver dysfunction as evidenced by at least 5 times greater than upper
             limits of normal baseline ALT (alanine aminotransferase) , AST (aspartate
             aminotransferase), alkaline phosphatase, or total bilirubin.

          2. Use of an alternative antifungal therapy (IV or oral) for more than 14 days for this
             infection.

          3. Evidence of CNS (central nervous system) infection.

          4. Unable to take PO medications.

          5. Female patients who are lactating or pregnant.

             Women should be:

               1. Postmenopausal for 1 year,

               2. Post-hysterectomy or bilateral oophorectomy,

               3. If of child bearing potential have a negative Î²-HCG (human chorionic
                  gonadotropin) at screening and using highly effective method of birth control
                  throughout course of study or remain abstinent for duration of study.

          6. Documented intolerance, allergy or hypersensitivity to an azole.

          7. Inability to comply with study treatment, study visits, and study procedures.

          8. Known history of congestive cardiac failure on medical treatment, fungal endocarditis,
             or other causes of ventricular dysfunction that may outweigh the benefit of
             itraconazole.

          9. Patients with active TB (tuberculosis)

         10. Concurrent use of astemizole, rifampin/rifampicin, rifabutin, ergot alkaloids, long
             acting barbiturates, carbamazepine, pimozide, quinidine, neostigmine, terfenadine,
             ketoconazole, valproic acid, or St. John's wort in the 5 days prior to first
             administration of study drug.

         11. Any known or suspected condition of the patient that may jeopardize adherence to the
             protocol requirements or impede the accurate measurement of efficacy.

         12. Treatment with any investigational agent in the 30 days prior to study entry.

         13. Patients unlikely to survive 30 days (including severe fungal disease defined by
             systolic blood pressure (SBP) &lt; 90; hypoxia &lt; 60).

         14. Patients with body weight &lt; 40 kg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter G Pappas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George R Thompson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrej Spec, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alisa Peinhardt</last_name>
    <phone>205-934-9661</phone>
    <email>apeinhardt@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel McMullen</last_name>
    <phone>205-934-7292</phone>
    <email>rlmcmullen@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisa Peinhardt, MAIS</last_name>
      <email>apeinhardt@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rachel McMullen, BS</last_name>
      <email>rlmcmullen@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Peter G Pappas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Barron</last_name>
      <phone>520-626-5869</phone>
      <email>mbarron@email.arizona.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alexandria Chaput</last_name>
      <phone>520-626-5869</phone>
      <email>alexandriachaput@email.arizona.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Justin Hayes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Payton, MPH</last_name>
      <phone>916-734-8033</phone>
      <email>cpayton@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>George R Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Mall</last_name>
      <phone>312-942-4810</phone>
      <email>mark_mall@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Laurie Proia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Woods</last_name>
      <phone>734-647-9830</phone>
      <email>woodsand@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Marisa Miceli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Hubert, RN</last_name>
      <phone>314-747-1922</phone>
      <email>sarahubert@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Andrej Spec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710-1000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>June Carbonneau, CRC Sr</last_name>
      <phone>919-668-0166</phone>
      <email>june.carbonneau@duke.edu</email>
    </contact>
    <investigator>
      <last_name>John Perfect, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meg Bayless, RN</last_name>
      <phone>608-263-1546</phone>
      <email>mbayless@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>David Andes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Peter Pappas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

